Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Akebia Therapeutics announced a senior secured term loan facility with Symbiotic Capital consisting of an initial $60 million tranche (fully funded) and up to an additional $80 million available at Symbiotic's discretion. The company used proceeds to fully repay its $55 million BlackRock loan facility. The facility has a 60-month maturity with interest-only payments for 60 months and bears interest at the greater of WSJ Prime plus 4.5% or 11.5%. Akebia reaffirmed its cash runway guidance of at least two years.


